Physician profile
Michael E Sabol
NPI 1326135872
$9,467.75
in general payments reported to CMS, 2019-2025
32 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,391 · 2022: $2,025 · 2023: $2,395 · 2024: $2,091 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,500 · Education: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,499.91 |
| Education | $551.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.87 | 2021-2025 | |
| Pfizer INC. | $1,007.70 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $982.94 | 2021-2025 | Ilumya |
| Janssen Biotech, INC. | $840.74 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $771.17 | 2022-2025 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $696.55 | 2022-2025 | Neuac, Clindacin Etz, Tovet (Emollient Formulation) |
| Genzyme Corporation | $585.28 | 2021-2024 | |
| Leo Pharma INC. | $429.03 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $367.95 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $316.01 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $304.60 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $289.64 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $230.41 | 2021-2025 | Aklief, Oracea, Epsolay |
| Janssen Scientific Affairs, LLC | $227.49 | 2021-2022 | |
| Dermavant Sciences, INC. | $193.03 | 2022-2024 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $125.81 | 2021-2024 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $70.45 | 2021-2025 | |
| Sandoz INC. | $69.52 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.36 | 2023-2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $54.05 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.29 | 2023 | Jublia |
| Genentech USA, INC. | $45.96 | 2021-2024 | Erivedge |
| Ani Pharmaceuticals, INC. | $41.46 | 2023 | Veregen |
| Organogenesis INC. | $36.94 | 2023-2024 | Puraply, Apligraf |
| Incyte Corporation | $34.07 | 2022-2025 | Opzelura |
| Biocon Biologics INC | $20.27 | 2024 | Hulio |
| Fresenius Kabi USA, LLC | $19.66 | 2023 | Idacio |
| Organon LLC | $17.22 | 2024 | |
| Biofrontera INC. | $16.50 | 2021 | |
| Botanix Sb INC | $14.10 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sabol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.